<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Rui Tian | Academic Portfolio</title>
    <style>
        :root {
            --primary: #0a2e50;
            --accent: #d4af37;
            --text: #2c3e50;
            --glass: rgba(255, 255, 255, 0.9);
        }

        body {
            font-family: 'Optima', 'Palatino', 'Segoe UI', serif;
            background: radial-gradient(circle at top right, #f8f9fc, #e3eaf2);
            color: var(--text);
            margin: 0; padding: 0; line-height: 1.6;
            background-attachment: fixed;
        }

        /* Á≤íÂ≠êËÉåÊôØË£ÖÈ•∞ */
        body::before {
            content: "";
            position: fixed;
            top: 0; left: 0; width: 100%; height: 100%;
            background-image: radial-gradient(var(--accent) 0.5px, transparent 0.5px);
            background-size: 30px 30px;
            opacity: 0.12;
            z-index: -1;
        }

        .container { max-width: 1300px; margin: 40px auto; padding: 0 40px; }

        header {
            text-align: left;
            border-bottom: 3px solid var(--primary);
            padding-bottom: 30px;
            margin-bottom: 50px;
        }

        header h1 { font-size: 3.8em; margin: 0; letter-spacing: 6px; color: var(--primary); font-weight: 800; }
        .contact { font-size: 1.1em; color: #5d6d7e; margin-top: 10px; font-weight: 500; }

        /* Â∏ÉÂ±ÄÔºöÂÜçÊ¨°Âä†ÂÆΩ‰æßËæπÊ†èÊØî‰æã‰ª•ÈÄÇÈÖçÂ§ßÂõæ */
        .layout { display: grid; grid-template-columns: 1.4fr 1.1fr; gap: 60px; }

        h2 {
            font-size: 1.5em; color: var(--primary); text-transform: uppercase;
            letter-spacing: 2.5px; border-left: 6px solid var(--accent);
            padding-left: 18px; margin: 45px 0 25px 0;
            background: linear-gradient(to right, rgba(212,175,55,0.1), transparent);
        }

        .item { margin-bottom: 30px; border-bottom: 1px solid rgba(0,0,0,0.05); padding-bottom: 15px; }
        .item-header { display: flex; justify-content: space-between; font-weight: bold; color: var(--primary); font-size: 1.1em; }
        .courses { font-size: 0.9em; color: #666; font-style: italic; margin-top: 8px; border-left: 2px solid #ddd; padding-left: 10px; }

        .pub-list { list-style: none; padding: 0; }
        .pub-item { margin-bottom: 40px; }
        .authors { font-size: 0.95em; color: #555; display: block; margin-top: 5px; }
        .me { font-weight: bold; text-decoration: underline; color: #000; }
        .pdf-link { color: #d35400; font-weight: bold; text-decoration: none; margin-left: 10px; font-size: 0.9em; }
        
        .abstract { font-size: 0.9em; color: #555; background: rgba(255,255,255,0.6); padding: 12px; border-radius: 6px; margin: 10px 0; border: 1px solid #eee; text-align: justify; }
        .contrib { font-size: 0.85em; color: #996515; font-weight: bold; display: block; margin-top: 5px; }

        /* ‰æßËæπÊ†èÂèäÂ§ßÂõæÂ∏ÉÂ±Ä‰ºòÂåñ */
        .sidebar { position: sticky; top: 20px; }
        .visual-card {
            background: #fff; border: 1px solid #eef2f6; padding: 25px;
            border-radius: 15px; margin-bottom: 40px; box-shadow: 0 15px 35px rgba(0,0,0,0.08);
        }
        .visual-img {
            width: 100%; height: 320px; background: #f8fafc; border-radius: 10px;
            margin-bottom: 15px; display: flex; align-items: center; justify-content: center;
            color: #bdc3c7; font-size: 0.9em; background-size: contain; background-repeat: no-repeat; background-position: center;
            border: 1px solid #e2e8f0;
        }
        .arrow-hint {
            color: var(--accent); font-size: 1.3em; font-weight: bold;
            display: flex; align-items: center; margin-bottom: 15px;
        }
        .arrow-hint::before { content: "‚û§"; margin-right: 15px; animation: slide 1.5s infinite ease-in-out; }

        @keyframes slide { 0% { transform: translateX(0); } 50% { transform: translateX(12px); } 100% { transform: translateX(0); } }

        .tag { display: inline-block; background: #f0f4f8; padding: 4px 12px; border-radius: 50px; font-size: 0.85em; margin: 3px; color: var(--primary); border: 1px solid #d1d9e6; font-weight: 500; }

        @media (max-width: 1024px) { .layout { grid-template-columns: 1fr; } .sidebar { position: static; } }
    </style>
</head>
<body>

<div class="container">
    <header>
        <h1>RUI TIAN</h1>
        <div class="contact">
            üìß christy.terence0111@gmail.com &nbsp;&nbsp; | &nbsp;&nbsp; üìû (+86) 152 2391 4429
        </div>
    </header>

    <div class="layout">
        <main>
            <section>
                <h2>Education</h2>
                <div class="item">
                    <div class="item-header"><span>Xiamen University</span><span>2019.09 - 2022.06</span></div>
                    <div>M.S. in Translational Medicine (Biomedicine) | GPA: 84/100</div>
                    <div class="courses">Key Courses: Advanced courses on biological products, Translational Medicine, Science Writing.</div>
                </div>
                <div class="item">
                    <div class="item-header"><span>Chongqing Medical University</span><span>2015.09 - 2019.06</span></div>
                    <div>B.S. in Sanitary Inspection and Quarantine | Rank: 3/82 (Top 3.7%) | GPA: 86.15/100</div>
                    <div class="courses">Key Courses: Molecular Biology, Medical Immunology, Genetic Medicine, Biochemistry, Basic Computer Programming.</div>
                </div>
            </section>

            <section>
                <h2>Research Experience</h2>
                <div class="item">
                    <strong>1. Elucidated the Crucial Epitope of HSV gD</strong>
                    <p style="font-size: 0.9em; color: #666; margin: 5px 0;">Xiamen University | 2019 - 2022</p>
                    <ul>
                        <li>Screened five potent neutralizing antibodies (NAbs) against HSV-1/2 from immunized mice.</li>
                        <li>Identified a conserved continuous epitope (262‚Äì272 aa) on glycoprotein D (gD) that blocks binding to host receptor Nectin-1.</li>
                        <li>Characterized antibody-epitope interactions through neutralization assays and epitope mapping.</li>
                    </ul>
                </div>

                <div class="item">
                    <strong>2. Screened and Validated Host Intrinsic Restriction Factors (HIR Factors)</strong>
                    <p style="font-size: 0.9em; color: #666; margin: 5px 0;">Xiamen University | 2019 - 2022</p>
                    <ul>
                        <li>Identified 16 interferon-related genes (IRGs) significantly upregulated after oHSV-1 infection by RNA sequencing.</li>
                        <li>Generated 16 CRISPR/Cas9 knockout cell lines to validate HIR factors on oncolytic virus-resistant cells.</li>
                        <li>Uncovered the key mechanism of HSV-1 infection using RNA sequencing, R programming, and immunoprecipitation.</li>
                    </ul>
                </div>

                <div class="item">
                    <strong>3. Platform Establishment & Gene Modulation (Work Experience)</strong>
                    <p style="font-size: 0.9em; color: #666; margin: 5px 0;">CQMU Cancer Hospital | 09/2022 - Present</p>
                    <ul>
                        <li>Established a lentiviral vector-based platform for gene overexpression and silencing.</li>
                        <li>Developed CRISPR/Cas9-based workflows for generating knockout cell lines.</li>
                        <li>Managed daily lab operations and implemented PI's research projects in cancer epigenetics.</li>
                    </ul>
                </div>
            </section>

            <section>
                <h2>Publications</h2>
                <div class="pub-list">
                    <div class="pub-item">
                        <span><strong>[1]</strong> A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D</span> <a href="pub1.pdf" class="pdf-link" target="_blank">[PDF]</a>
                        <span class="authors"><span class="me">Rui Tian</span>, et al. <em>Antiviral Research</em>, 2022.</span>
                        <div class="abstract"><strong>Main Content:</strong> This study isolated five potent NAbs. MAb 2C10 exhibited strong neutralization against HSV-1 and HSV-2 by targeting a conserved continuous epitope (262‚Äì272 aa) on gD, effectively blocking Nectin-1 interaction and showing in vivo protective efficacy.</div>
                        <span class="contrib">Contribution: Manuscript writing, data processing, antibody identification & evaluation, cell culture, and epitope exploration.</span>
                    </div>

                    <div class="pub-item">
                        <span><strong>[2]</strong> Oncolytic virus expressing PD-1 inhibitors activates collaborative intratumoral immune response</span> <a href="pub2.pdf" class="pdf-link" target="_blank">[PDF]</a>
                        <span class="authors">F. Ju, ..., <span class="me">Rui Tian</span>, et al. <em>Journal for ImmunoTherapy of Cancer</em>, 2022.</span>
                        <div class="abstract"><strong>Main Content:</strong> Developed an oncolytic HSV expressing PD-1 inhibitors (oHSV-scFv-PD-1). This strategy localizes PD-1 blockade to the tumor, synergizing with the virus to reprogram the immune microenvironment and enhance T-cell activity.</div>
                        <span class="contrib">Contribution: Involved in cell culture, viral production, titration, and data processing.</span>
                    </div>

                    <div class="pub-item">
                        <span><strong>[3]</strong> The tumor suppressor DACT3 sensitizes TNBC to apatinib via Wnt/Œ≤-catenin pathway</span> <a href="pub5.pdf" class="pdf-link" target="_blank">[PDF]</a>
                        <span class="authors">J. Wu, <span class="me">Rui Tian</span>, et al. <em>Translational Oncology</em>, 2025.</span>
                        <div class="abstract"><strong>Main Content:</strong> Identified DACT3 as a critical regulator of apatinib sensitivity in Triple-Negative Breast Cancer. DACT3 inhibits the Wnt/Œ≤-catenin signaling axis, making it a potential biomarker for VEGFR2 inhibitor efficacy.</div>
                        <span class="contrib">Contribution: Molecular/cellular guidance, cell culture, data analysis, and manuscript revision.</span>
                    </div>

                    <div class="pub-item">
                        <span><strong>[4]</strong> The novel DNA methylation marker FIBIN suppresses non-small cell lung cancer metastasis</span> <a href="pub4.pdf" class="pdf-link" target="_blank">[PDF]</a>
                        <span class="authors">M. Peng, ..., <span class="me">Rui Tian</span>, et al. <em>Cellular Signalling</em>, 2024.</span>
                        <span class="contrib">Contribution: Involved in data analysis and manuscript revision.</span>
                    </div>

                    <div class="pub-item">
                        <span><strong>[5]</strong> PDCD2 as a prognostic biomarker in glioma correlates with malignant phenotype</span> <a href="pub3.pdf" class="pdf-link" target="_blank">[PDF]</a>
                        <span class="authors">F. Dai, ..., <span class="me">Rui Tian</span>, et al. <em>Genes & Diseases</em>, 2023.</span>
                        <span class="contrib">Contribution: Involved in data analysis and manuscript revision.</span>
                    </div>
                </div>
            </section>
        </main>

        <aside class="sidebar">
            <div class="visual-card">
                <div class="arrow-hint">Research Highlight [1]</div>
                <div class="visual-img" style="background-image: url('fig1.jpg');">Epitope Map & receptor Blockade</div>
                <p style="font-size: 0.85em; color: #666; font-weight: bold;">Structural mapping of gD conserved epitope (262‚Äì272 aa) blocking Nectin-1.</p>
            </div>

            <div class="visual-card">
                <div class="arrow-hint">Research Highlight [2]</div>
                <div class="visual-img" style="background-image: url('fig2.jpg');">oHSV-scFv-PD-1 Mechanism</div>
                <p style="font-size: 0.85em; color: #666; font-weight: bold;">Enhanced T-cell activation and tumor microenvironment reprogramming.</p>
            </div>

            <h2>Experimental Skills</h2>
            <div class="item">
                <div class="tag">Cell Culture</div> <div class="tag">CRISPR/Cas9</div> 
                <div class="tag">Lentiviral Platforms</div> <div class="tag">Viral Titration</div> 
                <div class="tag">Immunoprecipitation (IP)</div> <div class="tag">Flow Cytometry (FACS)</div> 
                <div class="tag">Confocal Microscopy</div> <div class="tag">Western Blot (WB)</div>
                <div class="tag">Molecular Cloning</div> <div class="tag">ELISA</div>
                <div class="tag">RNA-seq Analysis</div> <div class="tag">R Programming</div>
            </div>

            <h2>Honors & Awards</h2>
            <div style="font-size: 0.85em; line-height: 1.8; color: #444;">
                ‚Ä¢ Second prize, "Wan Fu Biology" award (2022.05)<br>
                ‚Ä¢ Research innovation award, XMU (top 3%, 2022.01)<br>
                ‚Ä¢ Outstanding individual award, XMU (top 5%, 2021.01)<br>
                ‚Ä¢ Excellent thesis award, CQMU (top 1%, 2019.06)<br>
                ‚Ä¢ Merit student scholarship, CQMU (top 2%, 2018.07)<br>
                ‚Ä¢ Merit student scholarship, CQMU (2017.07)<br>
                ‚Ä¢ Merit student scholarship, CQMU (2016.07)
            </div>
        </aside>
    </div>
</div>

</body>
</html>
